vs
BALCHEM CORP（BCPC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
BALCHEM CORP的季度营收约是Ultragenyx Pharmaceutical Inc.的1.3倍（$270.7M vs $207.3M），BALCHEM CORP净利率更高（14.9% vs -62.0%，领先76.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 8.1%），BALCHEM CORP自由现金流更多（$33.8M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 7.5%）
Balchem Corp是一家全球特种化学品与营养原料供应商，核心业务覆盖人类营养、动物保健、制药、工业应用四大领域，为北美、欧洲、亚太等地区的客户提供定制化专用原料产品。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BCPC vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $270.7M | $207.3M |
| 净利润 | $40.3M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 20.5% | -54.7% |
| 净利率 | 14.9% | -62.0% |
| 营收同比 | 8.1% | 25.9% |
| 净利润同比 | 8.7% | 3.5% |
| 每股收益（稀释后） | $1.25 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $270.7M | — | ||
| Q4 25 | $263.6M | $207.3M | ||
| Q3 25 | $267.6M | $159.9M | ||
| Q2 25 | $255.5M | $166.5M | ||
| Q1 25 | $250.5M | $139.3M | ||
| Q4 24 | $240.0M | $164.6M | ||
| Q3 24 | $239.9M | $139.5M | ||
| Q2 24 | $234.1M | $147.0M |
| Q1 26 | $40.3M | — | ||
| Q4 25 | $39.2M | $-128.6M | ||
| Q3 25 | $40.3M | $-180.4M | ||
| Q2 25 | $38.3M | $-115.0M | ||
| Q1 25 | $37.1M | $-151.1M | ||
| Q4 24 | $33.6M | $-133.2M | ||
| Q3 24 | $33.8M | $-133.5M | ||
| Q2 24 | $32.1M | $-131.6M |
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — |
| Q1 26 | 20.5% | — | ||
| Q4 25 | 19.8% | -54.7% | ||
| Q3 25 | 20.4% | -106.9% | ||
| Q2 25 | 20.1% | -64.8% | ||
| Q1 25 | 20.4% | -102.6% | ||
| Q4 24 | 19.8% | -74.3% | ||
| Q3 24 | 20.0% | -94.6% | ||
| Q2 24 | 19.6% | -79.1% |
| Q1 26 | 14.9% | — | ||
| Q4 25 | 14.9% | -62.0% | ||
| Q3 25 | 15.1% | -112.8% | ||
| Q2 25 | 15.0% | -69.0% | ||
| Q1 25 | 14.8% | -108.5% | ||
| Q4 24 | 14.0% | -80.9% | ||
| Q3 24 | 14.1% | -95.7% | ||
| Q2 24 | 13.7% | -89.5% |
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.21 | $-1.28 | ||
| Q3 25 | $1.24 | $-1.81 | ||
| Q2 25 | $1.17 | $-1.17 | ||
| Q1 25 | $1.13 | $-1.57 | ||
| Q4 24 | $1.03 | $-1.34 | ||
| Q3 24 | $1.03 | $-1.40 | ||
| Q2 24 | $0.98 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $72.9M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $-80.0M |
| 总资产 | $1.7B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | $72.9M | — | ||
| Q4 25 | $74.6M | $421.0M | ||
| Q3 25 | $65.1M | $202.5M | ||
| Q2 25 | $65.4M | $176.3M | ||
| Q1 25 | $49.9M | $127.1M | ||
| Q4 24 | $49.5M | $174.0M | ||
| Q3 24 | $73.7M | $150.6M | ||
| Q2 24 | $63.7M | $480.7M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $-80.0M | ||
| Q3 25 | $1.3B | $9.2M | ||
| Q2 25 | $1.3B | $151.3M | ||
| Q1 25 | $1.2B | $144.2M | ||
| Q4 24 | $1.1B | $255.0M | ||
| Q3 24 | $1.2B | $346.8M | ||
| Q2 24 | $1.1B | $432.4M |
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $1.5B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.7B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.6B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $40.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $33.8M | $-100.8M |
| 自由现金流率自由现金流/营收 | 12.5% | -48.6% |
| 资本支出强度资本支出/营收 | 2.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.99× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | $40.1M | — | ||
| Q4 25 | $67.3M | $-99.8M | ||
| Q3 25 | $65.6M | $-91.4M | ||
| Q2 25 | $47.3M | $-108.3M | ||
| Q1 25 | $36.5M | $-166.5M | ||
| Q4 24 | $52.3M | $-79.3M | ||
| Q3 24 | $51.3M | $-67.0M | ||
| Q2 24 | $45.0M | $-77.0M |
| Q1 26 | $33.8M | — | ||
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M |
| Q1 26 | 12.5% | — | ||
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% |
| Q1 26 | 2.3% | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% |
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCPC
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
